Also studies evaluating the successful treatment discontinuation in CML have suggested that IFN-α therapy may improve the possibility to stop TKI therapy [5], [12]. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.